Astragaloside IV

Astragaloside IV (AS-IV) is a cycloartane-type triterpenoid saponin glycoside and the principal pharmacologically active saponin constituent of Astragalus membranaceus (Huangqi), a botanical drug with over two thousand years of documented use in traditional Chinese medicine for tonification of qi, immune support, and cardiovascular health. The compound, bearing the molecular formula C41H68O14 and a molecular weight of 784.97, consists of a cycloartane aglycone skeleton conjugated to beta-D-glucose and beta-D-xylose sugar moieties. Astragaloside IV has emerged over the past two decades as one of the most extensively investigated natural product saponins in modern pharmacology, with a research literature now spanning cardioprotection, neuroprotection, hepatoprotection, nephroprotection, pulmonary fibrosis attenuation, anti-tumor activity, metabolic syndrome modulation, and telomerase activation through its principal gut-microbial metabolite cycloastragenol.

The molecular pharmacology of astragaloside IV is characterized by multi-target activity across several canonical signaling cascades. The compound inhibits the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) pathway through suppression of IkB phosphorylation and reduction of nuclear translocation, producing dose-dependent reductions in tumor necrosis factor alpha, interleukin-1 beta, and interleukin-6 in activated macrophages and in lipopolysaccharide-challenged animal models. Concurrently, astragaloside IV activates the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) antioxidant response element pathway, upregulating superoxide dismutase, glutathione peroxidase, and catalase expression. The compound modulates the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling axis with context-dependent activation (cardioprotection, neuroprotection) or inhibition (anti-tumor applications), and suppresses the transforming growth factor beta 1 (TGF-beta1)/Smad pathway to attenuate fibrotic remodeling in lung, liver, and kidney tissue. Additional characterized targets include Toll-like receptor 4 (TLR4), the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptor gamma (PPARgamma), and glycogen synthase kinase 3 beta (GSK3beta).

Pharmacokinetics present the principal translational challenge for astragaloside IV. Oral bioavailability in rats is approximately 2.2 to 3.7 percent, and in beagle dogs approximately 7.4 percent, reflecting high molecular weight, poor aqueous solubility, limited intestinal membrane permeability, and predominantly paracellular absorption. The compound undergoes extensive biotransformation by intestinal microflora (principally Bifidobacteria and Lactobacillus species) through sequential deglycosylation to produce cycloastragenol, the aglycone metabolite that is substantially more bioavailable and that mediates telomerase activation through upregulation of human telomerase reverse transcriptase (hTERT) gene expression via the mitogen-activated protein kinase (MAPK) pathway. Plasma elimination half-life in rats after oral administration is approximately 3.8 hours, with highest tissue concentrations in lung and liver.

The preclinical evidence base is extensive and spans multiple organ systems. In myocardial ischemia-reperfusion models, astragaloside IV at doses of 10 to 80 mg/kg reduces infarct size, improves ejection fraction, and attenuates apoptosis through PI3K/Akt and mitochondrial pathway modulation. In focal cerebral ischemia models, the compound reduces infarct volume and neurological deficit scores through Nrf2/HO-1 activation and NF-kB suppression. In carbon tetrachloride and high-fat-diet hepatotoxicity models, astragaloside IV preserves hepatocyte integrity through antioxidant and anti-inflammatory mechanisms. In diabetic nephropathy models, the compound attenuates glomerular basement membrane thickening and reduces proteinuria. In bleomycin-induced pulmonary fibrosis models, astragaloside IV suppresses collagen deposition through TGF-beta1/Smad pathway inhibition.

Clinical evidence in humans remains limited. Safety data from Phase 1 studies of an intravenous astragaloside IV preparation in healthy Chinese volunteers demonstrated tolerability at single doses of 200 to 600 milliliters (0.09 mg/mL) and multiple daily doses over one week without toxic reactions or plasma accumulation. Astragalus membranaceus extract preparations containing astragaloside IV as a standardized marker compound are registered in the Chinese Pharmacopoeia and are widely used in clinical practice in China, Japan, and the Republic of Korea for cardiovascular, hepatic, and immune-support indications. The telomerase-activating metabolite cycloastragenol is the active principle of the commercial nutraceutical TA-65, which has produced positive telomere-lengthening results in randomized controlled trials in middle-aged and older adults.

This monograph documents the chemistry, biosynthesis, and structural characterization of astragaloside IV; the multi-target molecular pharmacology across NF-kB, Nrf2, PI3K/Akt, TGF-beta1/Smad, TLR4, and telomerase pathways; the pharmacokinetic profile including the critical gut-microbial biotransformation to cycloastragenol; the preclinical evidence base across cardiovascular, neurological, hepatic, renal, pulmonary, metabolic, and oncological models; the limited clinical evidence; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event and safety data; and a comparative assessment of five structurally or functionally related triterpenoid saponins against astragaloside IV on five competency standards.